All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
As a leading and reliable service provider, Creative Biolabs is well known worldwide for its breakthrough in CAR production system. Based on targeting carcinoma-specific antigens in the follow table, our outstanding scientists have constructed diverse CAR-T cells or CAR NK cells targeting these antigens. In addition to these, Creative Biolabs can also customize CAR product according to your special requirements.
Vicki Brower. The CAR T-Cell Race. The scientist. 2015
As a group of cancer, carcinoma usually starts from skin and spreads to other organs of the body. It accounts for 90% of all cancers, which mostly occurs in adults, with the DNA mutation as its main cause. Based on the tissue which cancer cells arise from, the primary carcinoma category includes breast cancer, prostate cancer, colorectal cancer, lung malignancy, adenocarcinomas, cervical carcinoma, melanoma and renal cell carcinoma. The most common symptom is lump under the skin, while there're some other symptoms such as skin discolorations, pains. Although few strategies show effectiveness in carcinoma treatment, immunotherapy has performed great potential as a promising approach to treat carcinoma, such as CAR modified T cells or natural killer (NK) cells. Experts from Creative Biolabs can offer various CAR-T cell or NK cells construction services according to your request.
Based on a great amount of experiments, we are confident our first-class CAR products can greatly accelerate your project process. Please feel free to contact us at any time.
Products against Carcinoma-specific antigens
Associated malignancy | Target antigen | Receptor type | Product |
Renal cell carcinoma (RCC) | Carbonic anhydrase IX (CAIX) | scFv-CD28-41BB-CD3ζ | CAR-MZ204 |
CSPG4 | scFv-CD28-CD3ζ | CAR-LC134 | |
G250 epitope | iRGD-scFv-CD28-41BB-CD3ζ | CAR-LC371 | |
VEGFR-2 | scFv-CD28-41BB-CD3ζ | CAR-LC132 | |
scFv-CD28-CD3ζ | CAR-LC133 | ||
Melanoma | EGFR | scFv-CD3ζ | CAR-LC097 |
scFv-CD28-CD3ζ | CAR-LC098 | ||
scFv-CD28-41BB-CD3ζ | CAR-LC100 | ||
Trop2 | scFv-CD28-41BB-CD3ζ | CAR-LC190 | |
PD-L1 | PD1-41BB-CD3ζ | CAR-LC282 | |
Cs-1 | scFv (SLAMF7)-CD28-41BB-CD3ζ/scFv (FN)-cMYCmu | CAR-LC365 | |
BCMA | scFv-CD28-41BB-CD3ζ | CAR-T-3-L335-2BZ | |
CS1 | scFv-CD28-OX40-CD3ζ | CAR-NK-3-M329-2XZ | |
CSH1 | scFv-CD28-41BB-CD3ζ | CAR-T-3-L349-2BZ | |
HMW-MAA | scFv-CD28-41BB-CD3ζ | CAR-T-3-M318-2BZ | |
NY-ESO-1 | scFv-CD28-41BB-CD3ζ | CAR-T-3-M323-2BZ | |
GD3 | scFv-CD28-41BB-CD3ζ | CAR-T-3-M317-2BZ | |
MART-1(DMF5) | scFv-CD28-41BB-CD3ζ | CAR-T-3-M310-2BZ | |
CD56 | scFv-CD28-41BB-CD3ζ | CAR-T-3-M312-2BZ | |
gp100 | VHH-41BB-CD3ζ | CAR-T-2-M552-BZ | |
Lung malignancy | Mesothelin | scFv-CD28-41BB-CD3ζ | CAR-LC054 |
scFv-CD3ζ | CAR-LC023 | ||
scFv-CD28-CD3ζ | CAR-LC024 | ||
ALK | scFv-CD28-41BB-CD3ζ | CAR-LC103 | |
Fibroblast activation protein (FAP) | scFv-41BB-CD3ζ | CAR-LC224 | |
CD87 | scFv-41BB-CD3ζ-IL12 | CAR-LC265 | |
Tissue factor | Protein-41BB-CD3ζ | CAR-LC288 | |
TF | scFv-CD28-OX40-CD3ζ | CAR-T-3-L406-2XZ | |
Colorectal cancer | CEA | scFv-CD28-41BB-CD3ζ | CAR-T-3-M314-2BZ |
EGP-2 | scFv-CD28-41BB-CD3ζ | CAR-T-3-M316-2BZ | |
TAG-72 | scFv-CD28-41BB-CD3ζ | CAR-T-3-M325-2BZ | |
CD276 | scFv-CD28-CD3ζ | CAR-LC162 | |
EpCAM | scFv-CD28-41BB-CD3ζ | CAR-LC181 | |
HLA-A2-WT1DB126 | scFv-CD28-FcγR1γ | CAR-LC266 | |
Prostate cancer | PSMA | scFv-CD28-OX40-CD3ζ | CAR-T-3-L336-2XZ |
PSCA | scFv-CD28-CD3ζ | CAR-MZ157 | |
Breast cancer | CD8 | scFv-CD28-41BB-CD3ζ | CAR-T-3-L348-2BZ |
ErbB2 | scFv-CD28-41BB-CD3ζ | CAR-T-3-L337-2BZ | |
MUC1 | scFv-CD28-41BB-CD3ζ | CAR-T-3-M322-2BZ | |
TEM8 | scFv-CD28-41BB-CD3ζ | CAR-T-3-L343-2BZ | |
SSEA4 | scFv-41BB-CD3ζ | CAR-LC001 | |
CD33 | scFv-CD28-CD3ζ | CAR-LC155 | |
HER2 | scFv-41BB-CD3ζ | CAR-LC172 | |
NY-BR-1 | scFv-CD28-41BB-CD3ζ | CAR-LC220 | |
CD44 | scFv-CD28-CD3ζ | CAR-LC226 | |
CD47 | scFv (CD47)-CD28-41BB-CD3ζ/scFv (TAZ)-TET2 | CAR-LC364 |
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION